(ALMDT) Mediantechn - Overview
Exchange: PA •
Country: France •
Currency: EUR •
Type: Common Stock •
ISIN: FR0011049824
Stock: iBiops, iSee, iCRO
Total Rating 39
Risk 38
Buy Signal 0.22
| Risk 5d forecast | |
|---|---|
| Volatility | 93.7% |
| Relative Tail Risk | -20.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.95 |
| Alpha | 78.51 |
| Character TTM | |
|---|---|
| Beta | 0.443 |
| Beta Downside | 0.974 |
| Drawdowns 3y | |
|---|---|
| Max DD | 86.02% |
| CAGR/Max DD | -0.23 |
Description: ALMDT Mediantechn December 22, 2025
Median Technologies SA (ALMDT) creates AI-driven software platforms for medical image analysis, serving markets in France, the U.S., Canada, the U.K., China, and other regions. Its flagship products include iBiops, a CE-marked AI-enabled diagnostic tool for early detection of cancers and fibrotic diseases; iSee, which provides image-analysis services for clinical-trial sponsors; and iCRO, a software-based imaging-service offering for oncology trials.
In 2023 the company reported roughly €30 million in revenue, up about 12% year-over-year, with R&D consuming ~20% of sales-reflecting its focus on maintaining a pipeline of FDA-cleared AI algorithms. The global AI-based medical imaging market is projected to grow at a CAGR of ~15% through 2030, driven by rising cancer incidence, aging populations, and expanding reimbursement for digital diagnostics, all of which underpin Median’s growth outlook.
For a deeper quantitative view, consider reviewing ValueRay’s analyst model on ALMDT to assess the stock’s risk-adjusted upside.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -47.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -1.79 > 0.02 and ΔFCF/TA -46.99 > 1.0 |
| NWC/Revenue: -59.41% < 20% (prev -0.22%; Δ -59.19% < -1%) |
| CFO/TA -1.70 > 3% & CFO -33.0m > Net Income -47.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 0.35 > 1.5 & < 3 |
| Outstanding Shares: last quarter (19.4m) vs 12m ago 23.06% < -2% |
| Gross Margin: -58.41% > 18% (prev -0.67%; Δ -5774 % > 0.5%) |
| Asset Turnover: 217.4% > 50% (prev 155.2%; Δ 62.20% > 0%) |
| Interest Coverage Ratio: -4.95 > 6 (EBITDA TTM -39.3m / Interest Expense TTM 8.34m) |
Altman Z'' -15.00
| A: -1.40 (Total Current Assets 14.8m - Total Current Liabilities 41.9m) / Total Assets 19.4m |
| B: -1.30 (Retained Earnings -25.2m / Total Assets 19.4m) |
| C: -1.97 (EBIT TTM -41.3m / Avg Total Assets 21.0m) |
| D: -2.34 (Book Value of Equity -139.9m / Total Liabilities 59.9m) |
| Altman-Z'' Score: -29.06 = D |
Beneish M -3.18
| DSRI: 1.10 (Receivables 9.43m/6.58m, Revenue 45.6m/35.0m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.52 (AQ_t 0.12 / AQ_t-1 0.08) |
| SGI: 1.30 (Revenue 45.6m / 35.0m) |
| TATA: -0.74 (NI -47.3m - CFO -33.0m) / TA 19.4m) |
| Beneish M-Score: -3.18 (Cap -4..+1) = AA |
What is the price of ALMDT shares?
As of February 08, 2026, the stock is trading at EUR 4.28 with a total of 136,547 shares traded.
Over the past week, the price has changed by +3.38%, over one month by +9.74%, over three months by +55.64% and over the past year by +35.87%.
Over the past week, the price has changed by +3.38%, over one month by +9.74%, over three months by +55.64% and over the past year by +35.87%.
Is ALMDT a buy, sell or hold?
Mediantechn has no consensus analysts rating.
What are the forecasts/targets for the ALMDT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8 | 86.4% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 4.4 | 1.6% |
ALMDT Fundamental Data Overview February 04, 2026
Market Cap USD = 203.3m (172.3m EUR * 1.1801 EUR.USD)
P/S = 7.3666
P/B = 252.6595
Revenue TTM = 45.6m EUR
EBIT TTM = -41.3m EUR
EBITDA TTM = -39.3m EUR
Long Term Debt = 8.71m EUR (from longTermDebt, last fiscal year)
Short Term Debt = 22.3m EUR (from shortTermDebt, last quarter)
Debt = 39.0m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 34.7m EUR (from netDebt column, last quarter)
Enterprise Value = 206.9m EUR (172.3m + Debt 39.0m - CCE 4.35m)
Interest Coverage Ratio = -4.95 (Ebit TTM -41.3m / Interest Expense TTM 8.34m)
EV/FCF = -5.94x (Enterprise Value 206.9m / FCF TTM -34.9m)
FCF Yield = -16.84% (FCF TTM -34.9m / Enterprise Value 206.9m)
FCF Margin = -76.38% (FCF TTM -34.9m / Revenue TTM 45.6m)
Net Margin = -103.7% (Net Income TTM -47.3m / Revenue TTM 45.6m)
Gross Margin = -58.41% ((Revenue TTM 45.6m - Cost of Revenue TTM 72.3m) / Revenue TTM)
Gross Margin QoQ = -42.60% (prev -108.9%)
Tobins Q-Ratio = 10.65 (Enterprise Value 206.9m / Total Assets 19.4m)
Interest Expense / Debt = 7.84% (Interest Expense 3.06m / Debt 39.0m)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -31.0m (EBIT -41.3m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 0.35 (Total Current Assets 14.8m / Total Current Liabilities 41.9m)
Debt / Equity = -0.96 (negative equity) (Debt 39.0m / totalStockholderEquity, last quarter -40.5m)
Debt / EBITDA = -0.88 (negative EBITDA) (Net Debt 34.7m / EBITDA -39.3m)
Debt / FCF = -0.99 (negative FCF - burning cash) (Net Debt 34.7m / FCF TTM -34.9m)
Total Stockholder Equity = -26.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -225.5% (out of range, set to none)
RoE = 177.2% (negative equity) (Net Income TTM -47.3m / Total Stockholder Equity -26.7m)
RoCE = 229.3% (negative capital employed) (EBIT -41.3m / Capital Employed (Equity -26.7m + L.T.Debt 8.71m))
RoIC = -1143 % (out of range, set to none) (NOPAT -31.0m / Invested Capital 2.71m)
WACC = 7.24% (E(172.3m)/V(211.3m) * Re(7.55%) + D(39.0m)/V(211.3m) * Rd(7.84%) * (1-Tc(0.25)))
Discount Rate = 7.55% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -3.71%
Fair Price DCF = unknown (Cash Flow -34.9m)
EPS Correlation: 23.89 | EPS CAGR: 69.32% | SUE: -1.26 | # QB: 0
Revenue Correlation: 70.28 | Revenue CAGR: 19.63% | SUE: 0.00 | # QB: 0
EPS next Year (2026-12-31): EPS=-0.49 | Chg30d=-0.081 | Revisions Net=-1 | Growth EPS=+37.5% | Growth Revenue=+28.9%
P/S = 7.3666
P/B = 252.6595
Revenue TTM = 45.6m EUR
EBIT TTM = -41.3m EUR
EBITDA TTM = -39.3m EUR
Long Term Debt = 8.71m EUR (from longTermDebt, last fiscal year)
Short Term Debt = 22.3m EUR (from shortTermDebt, last quarter)
Debt = 39.0m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 34.7m EUR (from netDebt column, last quarter)
Enterprise Value = 206.9m EUR (172.3m + Debt 39.0m - CCE 4.35m)
Interest Coverage Ratio = -4.95 (Ebit TTM -41.3m / Interest Expense TTM 8.34m)
EV/FCF = -5.94x (Enterprise Value 206.9m / FCF TTM -34.9m)
FCF Yield = -16.84% (FCF TTM -34.9m / Enterprise Value 206.9m)
FCF Margin = -76.38% (FCF TTM -34.9m / Revenue TTM 45.6m)
Net Margin = -103.7% (Net Income TTM -47.3m / Revenue TTM 45.6m)
Gross Margin = -58.41% ((Revenue TTM 45.6m - Cost of Revenue TTM 72.3m) / Revenue TTM)
Gross Margin QoQ = -42.60% (prev -108.9%)
Tobins Q-Ratio = 10.65 (Enterprise Value 206.9m / Total Assets 19.4m)
Interest Expense / Debt = 7.84% (Interest Expense 3.06m / Debt 39.0m)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -31.0m (EBIT -41.3m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 0.35 (Total Current Assets 14.8m / Total Current Liabilities 41.9m)
Debt / Equity = -0.96 (negative equity) (Debt 39.0m / totalStockholderEquity, last quarter -40.5m)
Debt / EBITDA = -0.88 (negative EBITDA) (Net Debt 34.7m / EBITDA -39.3m)
Debt / FCF = -0.99 (negative FCF - burning cash) (Net Debt 34.7m / FCF TTM -34.9m)
Total Stockholder Equity = -26.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -225.5% (out of range, set to none)
RoE = 177.2% (negative equity) (Net Income TTM -47.3m / Total Stockholder Equity -26.7m)
RoCE = 229.3% (negative capital employed) (EBIT -41.3m / Capital Employed (Equity -26.7m + L.T.Debt 8.71m))
RoIC = -1143 % (out of range, set to none) (NOPAT -31.0m / Invested Capital 2.71m)
WACC = 7.24% (E(172.3m)/V(211.3m) * Re(7.55%) + D(39.0m)/V(211.3m) * Rd(7.84%) * (1-Tc(0.25)))
Discount Rate = 7.55% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -3.71%
Fair Price DCF = unknown (Cash Flow -34.9m)
EPS Correlation: 23.89 | EPS CAGR: 69.32% | SUE: -1.26 | # QB: 0
Revenue Correlation: 70.28 | Revenue CAGR: 19.63% | SUE: 0.00 | # QB: 0
EPS next Year (2026-12-31): EPS=-0.49 | Chg30d=-0.081 | Revisions Net=-1 | Growth EPS=+37.5% | Growth Revenue=+28.9%